STAGE II PANCREATIC CANCER AJCC V8

This early-phase study tests whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. About 18 participants will receive the combination after i…

This study tests whether a combination of two drugs, lenvatinib and pembrolizumab, can help keep advanced pancreatic cancer from getting worse. The trial involves 28 adults whose cancer has spread and cannot be surgically removed, and who have already responded to initial treatme…

This study tests a new method called sonoporation, which uses ultrasound and tiny gas bubbles to help chemotherapy drugs get into cancer cells more effectively. The trial includes 120 adults with advanced or hard-to-remove pancreatic cancer who are already receiving standard chem…

This early-stage trial tests two drugs together for people with advanced pancreatic cancer. One drug starves cancer cells by removing a key nutrient, while the other blocks a protein that helps them grow. The goal is to find the safest dose and see if the combination can control …

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy with immunotherapy drugs and standard chemo to see if it's safe and what dose works best. About 74 a…

This early-phase study tests whether adding the blood pressure drug losartan to a shorter, stronger course of radiation therapy can help treat pancreatic cancer that is either borderline removable or has spread locally. Losartan may improve blood flow and oxygen in the tumor, mak…

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …